Thalassemia intermedia today: Should patients regularly receive transfusions?

Transfusion

Volumn 47, Issue 5, 2007, Pages 792-800

  Aessopos, Athanassios ^a   Kati, Maria ^a   Meletis, John ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CHELATING AGENT; IRON CHELATING AGENT;

ARTICLE; BETA THALASSEMIA; BLOOD TRANSFUSION; BONE MALFORMATION; CHELATION THERAPY; DISEASE COURSE; DISEASE SEVERITY; EXTRAMEDULLARY HEMATOPOIESIS; FRACTURE; HEMOLYTIC ANEMIA; HEPATOMEGALY; HUMAN; HYPERCOAGULABILITY; HYPOXEMIA; PULMONARY HYPERTENSION; SPLENOMEGALY; SURVIVAL; THALASSEMIA INTERMEDIA;

ANEMIA; BETA-THALASSEMIA; BLOOD TRANSFUSION; CHELATION THERAPY; COMBINED MODALITY THERAPY; HUMANS; TIME FACTORS;

EID: 34247644034     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2007.01192.x     Document Type: Article

References (70)

1. Olivieri NF. The β-thalassemias. N Engl J Med 1999 341 : 99 109.
2. Kanavakis E, Traeger-Synodinos J, Tzetis M, et al. Molecular characterization of homozygous (high HbA2) beta-thalassemia intermedia in Greece. Pediatr Hematol Oncol 1995 12 : 37 45.
3. Camaschella C, Cappellini MD. Thalassemia intermedia. Haematologica 1995 80 : 58 68.
4. Galanello R, Cao A. Relationship between genotype and phenotype: thalassemia intermedia. Ann N Y Acad Sci 1998 850 : 325 33.
5. Phadke SR, Agarwal S. Phenotype score to grade the severity of thalassemia intermedia. Indian J Pediatr 2003 70 : 477 81.
6. Moorchung N, Arya V, Agarwal S. Modifier genes and beta thalasaemia intermedia. Haema 2006 9 : 505 10.
7. Camaschella C, Mazza U, Roetto A, et al. Genetic interactions in thalassemia intermedia: analysis of beta-mutations, alpha-genotype, gamma-promoters, and beta-LCR hypertensive sites 2 and 4 in Italian patients. Am J Hematol 1995 48 : 82 7.
8. Mohamed N, Jackson N. Severe thalassemia intermedia: clinical problems in the absence of hypertransfusion. Blood Rev 1998 12 : 163 70.
9. Galanello R, Piras S, Barella S, et al. Cholelithiasis and Gilbert's syndrome in homozygous beta-thalassaemia. Br J Haematol 2001 115 : 926 8.
10. Gimmon Z, Wexler MR, Rachmilevitz EA. Pathogenesis of juvenile leg ulcers in β-thalassemia-major and intermedia. Plast Reconstr Surg 1982 69 : 320 3.
11. Aessopos A, Farmakis D, Loukopoulos D. Elastic tissue abnormalities resembling pseudoxantoma elasticum in β thalassemia and the sickling syndromes. Blood 2002 99 : 30 5.
12. Papanikolaou G, Tzilianos M, Christakis J, et al. Hepcidin in iron overload disorders. Blood 2005 105 : 4103 5.
13. Nemeth E, Ganz T. Hepcidin and iron-loading anemias. Haematologica 2006 91 : 727 32.
14. De Santis V, Tangerini VA, Testa MR, et al. Final height and endocrine function in thalassemia intermedia. J Pediatr Endocrinol Metab 1998 11 (Suppl 3 965 71.
15. Voskaridou E, Tempos E. New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia. Br J Haematol 2004 127 : 127 39.
16. Ashbell MB. Orthodontic aspects of Cooley's anemia. Ann N Y Acad Sci 1964 119 : 662 3.
17. Tassiopoulos S, Konstantopoulos K, Rombos Y, Aessopos A. Hemothorax due to extramedullary erythropoietic masses. Ann Thorac Surg 2004 77 : 323 4.
18. Dore F, Cianculli P, Rovasio S, et al. Incidence and clinical study of ectopic erythropoiesis in adult patients with thalassemia intermedia. Ann Ital Med Int 1992 7 : 137 40.
19. Chelal A, Aoun E, Koussa S, Skoury H, Koussa S, Taher A. Hypertension: a successful method of treatment in thalassemia intermedia patients with spinal cord compression secondary to extramedullary hematopoiesis. Spine 2003 28 : E245 9.
20. Aessopos A, Tassiopoulos S, Farmakis D, et al. Extramedullary hematopoiesis-related pleural effusion: case of β-thalassemia. Ann Thorac Surg 2006 81 : 2037 43.
21. Aessopos A, Farmakis D, Tsironi M, et al. Hemodynamic assessment of splenomegaly in β-thalassemia patients undergoing splenectomy. Ann Hematol 2004 83 : 775 8.
22. Mancuso A, Sciarrino E, Renda MC, Maggio A. A prospective study of hepatocellular carcinoma incidence in thalassemia. Hemoglobin 2006 30 : 119 24.
23. Aessopos A, Farmakis D, Deftereos S, et al. Cardiovascular effects of splenomegaly and splenectomy in beta-thalassemia. Ann Hematol 2005 84 : 353 7.
24. Aessopos A, Farmakis D. Pulmonary hypertension in β-thalassemia. Ann N Y Acad Sci 2005 1054 : 342 9.
25. Aessopos A, Politou M, Farmakis D, et al. Staphylococcus aureus abscess of the spleen in a beta-thalassemia patient. Scand J Infect Dis 2002 34 : 466 8.
26. Al-Hawsawi ZM, Hummaida TI. Splenic abscess in childhood B-thalassemia major. Saudi Med J 2002 23 : 345 7.
27. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and disease complications in thalassemia major. Ann N Y Acad Sci 1998 850 : 227 31.
28. Farmakis D, Giakoumis A, Polymeropoulos E, Aessopos A. Pathogenetic aspects of immune deficiency associated with beta-thalassemia. Med Sci Monit 2003 9 : RA19 22.
29. Walker EM, Walker SM. Effects of iron overload on the immune system. Ann Clin Lab Sci 2000 30 : 354 65.
30. Aswapokee N, Aswapokee P, Fucharoen S, Sukroongreung S, Wasi P. A study of infective episodes in patients with β-thalassemia/HbE disease in Thailand. Birth Defects Orig Artic Series 1987 23 : 513 20.
31. Aessopos A, Farmakis D, Karagiorga M, et al. Cardiac involvement in thalassemia intermedia: a multicenter study. Blood 2001 97 : 3411 6.
32. Singer ST, Wu V, Mignacca R, et al. Alloimmunization and erythrocyte autoimmunization in transfusion-dependent thalassemia patients of predominantly Asian descent. Blood 2000 96 : 3369 73.
33. Spanos T, Karageorga M, Ladis V, et al. Red cell alloantibodies in patients with thalassaemia. Vox Sang 1990 58 : 50 5.
34. Schonewille H, Van de Watering L, Loomans D, Brand A. Red blood cell alloantibodies after transfusion: factors influencing incidence and specificity. Transfusion 2006 46 : 250 6.
35. Bhatti FA, Salamat N, Nadeem A, Shabbir N. Red cell immunization in beta thalassemia major. J Coll Phys Surg Pak 2004 14 : 657 60.
36. Schonewille H, Haak HL, van Zijl AM. Alloimmunization after blood transfusion in patients with hematologic and oncologic diseases. Transfusion 1999 39 : 763 71.
37. Rebulla P, Modell B. Transfusion requirements and effects in patients with thalassaemia major. Cooleycare Programme. Lancet 1991 337 : 277 80.
38. Eldor A, Rachmilewitz EA. The hypercoagulable state in thalassemia. Blood 2002 99 : 36 43.
39. Borgna-Pignatti C, Carnelli V, Caruso V, et al. Thromoembolic events in beta-thalassemia major: an Italian multicenter study. Acta Haematol 1998 99 : 76 9.
40. Gillis S, Cappellini MD, Goldfarb A, et al. Pulmonary thromboembolism in thalassemia intermedia patients. Haematologica 1999 84 : 959 60.
41. Cappellini MD, Robbiolo L, Bottasso BM, et al. Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia. Br J Haematol 2000 111 : 467 73.
42. Cappellini MD, Grespi E, Cassinerio E, Bignamini D, Fiorelli G. Coagulation and splenectomy: an overview. Ann N Y Acad Sci 2005 1054 : 317 24.
43. Kyriakou DS, Alexandrakis MG, Kyriakou ES, et al. Activated peripheral blood and endothelial cells in thalassemia patients. Ann Hematol 2001 80 : 577 83.
44. Aessopos A, Savvides P, Stamatelos G, et al. Pseudoxantoma elasticum-like skin lesions and angioid streaks in beta-thalassemia. Am J Hematol 1992 41 : 159 64.
45. Hamlin N, Beck K, Bacchelli B, et al. Acquired Pseudoxantoma elasticum-like syndrome in beta-thalassaemia patients. Br J Haematol 2003 122 : 852 4.
46. Aessopos A, Farmakis D, Karagiorga M, Rombos I, Loukopoulos D. Pseudoxantoma elasticum lesions and cardiac complications as contributing factors for strokes in beta-thalassemia patients. Stroke 1997 28 : 2421 4.
47. Cheung YF, Chan GC, Ha SY. Arterial stiffness and endothelial function in patients with β-thalassemia major. Circulation 2002 106 : 2561 6.
48. Aessopos A, Samarkos M, Voskaridou E, et al. Arterial calcifications in beta-thalassemia. Angiology 1998 49 : 137 43.
49. Littera R, La Nasa G, Derchi G, et al. Long-term treatment with sildenafil in a thalassemic patient with pulmonary hypertension. Blood 2002 100 : 1516 7.
50. Derchi G, Forni GL, Formisano F, et al. Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathies. Haematologica 2005 90 : 452 8.
51. Derchi G, Forni GL. Therapeutic approaches to pulmonary hypertension in hemoglobinopathies: efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathy. Ann N Y Acad Sci 2005 1054 : 471 5.
52. Zakynthinos E, Vassilakopoulos T, Kaltsas P, et al. Pulmonary hypertension, interstizial lung fibrosis, and lung iron deposition in thalassemia major. Thorax 2001 56 : 737 9.
53. Aessopos A, Farmakis D, Deftereos S, et al. Thalassemia heart disease: a comparative evaluation of thalassemia major and thalassemia intermedia. Chest 2005 127 : 1523 30.
54. Vichinsky EP. Pulmonary hypertension in sickle cell disease. N Engl J Med 2004 350 : 857 9.
55. Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004 350 : 886 95.
56. Haque AK, Gokhale S, Rampy BA, et al. Pulmonary hypertension in sickle cell hemoglobinopathy. a clinicopathologic study of 20 cases. Hum Pathol 2002 33 : 1037 43.
57. Sonakul D, Fucharoen S. Pulmonary hypertension in thalassemic patients. Southeast Asian J Trop Med Pub Health 1992 23 (Suppl 2 25 8.
58. Davis BA, O'Sullivan C, Jarritt PH, Porter JB. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood 2004 104 : 263 9.
59. Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 2000 355 : 2051 2.
60. Borgna-Pignatti C, Rugoletto S, De Stefano P, et al. Survival and disease complications in thalassemia intermedia. Ann N Y Acad Sci 1998 850 : 227 31.
61. Prati D. Benefits and complications of regular blood transfusion in patients with beta-thalassemia major. Vox Sang 2000 79 : 129 37.
62. Engle MA, Erlandson M, Smith CH. Late cardiac complications of chronic, severe, refractory anemia with hemochromatosis. Circulation 1964 30 : 698 705.
63. Aessopos A, Farmakis D, Hatziliami A, et al. Cardiac status in well-treated patients with thalassemia major. Eur J Haematol 2004 73 : 359 66.
64. O'Driscoll A, Mackie IJ, Porter JB, Machin SJ. Low plasma heparin cofactor II levels in thalassaemia syndromes are corrected by chronic blood transfusion. Br J Haematol 1995 90 : 65 70.
65. Adams RJ, Brambilla D. Optimizing Primary Stroke Prevention in Sickle Cell Anemia (STOP 2) Trial Investigators. Discontinuing prophylatic transfusions used to prevent stroke in sickle cell disease. N Engl J Med 2005 353 : 2769 78.
66. Du ZD, Roguin N, Milgram E, Saab K, Koren A. Pulmonary hypertension in patients with thalassemia major. Am Heart J 1997 134 : 532 7.
67. Derchi G, Fonti A, Forni GL, et al. Pulmonary hypertension in patients with thalassemia major. Am Heart J 1997 138 : 384.
68. Anderson LJ, Holden S, Davis B, et al. Cariovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2000 22 : 2171 9.
69. Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006 107 : 3738 44.
70. Pakbaz Z, Fischer R, Treadwell M, et al. A simple model to assess and improve adherence to iron chelation therapy with deferoxamine in patients with thalassemia. Ann N Y Acad Sci 2005 1054 : 486 91.